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Conducting clinical trials in paediatric rheumatology has
been difficult in the past mainly because of the lack of
funding for academic studies and the lack of interest
by pharmaceutical companies for the small and non-
rewarding paediatric market. The situation changed dra-
matically few years ago with the introduction of the Best
Pharmaceuticals for Children Act in USA and of a specific
legislation for paediatric medicines development (Paedia-
tric Regulation) in the European Union (EU).
The main reasons for success are: the availability of
two large international non-for-profit networks working
in close collaboration, such as the Pediatric Rheumatology
Collaborative Study Group (PRCSG at http://www.prcsg.
org), covering North America, and the Paediatric Rheuma-
tology International Trials Organisation (PRINTO at
http://www.printo.it), covering more than 50 countries
worldwide; the availability of validated measures to evalu-
ate response to therapy, now called JIA American College
of Rheumatology (ACR) criteria, accepted by both the
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA); last but not least the advent of
the biologic therapies (anti TNF, Anti IL 1 and 6, anti
CTL4Ig) which have revolutionized juvenile idiopathic
arthritis (JIA) treatment.
Some problems however remain still to be solved: There
is a need to harmonise all the regulatory aspects related to
drugs that are used in the treatment of paediatric rheu-
matic diseases and in particular in JIA; the issue of me too
drugs; the issue of proper pK studies; the ethics of drugs
provision and of trial implementation; the implementation
of proper pharmacovigilance systems.
This presentation will review the reasons for success
and the problems that still remains to be solved for con-
ducting trials in JIA.
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